You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR DOXYLAMINE SUCCINATE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Doxylamine Succinate

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00796315 ↗ Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Completed Consumer Healthcare Products Association Phase 1 2008-12-01 The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years. Once characterized, these pediatric pharmacokinetic data will be pooled with historical adult PK data from other studies to assess whether the existing Over-the-Counter (OTC)doses provide comparable systemic drug exposure as that associated with efficacy in adults.
OTC NCT00796315 ↗ Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Completed Procter and Gamble Phase 1 2008-12-01 The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years. Once characterized, these pediatric pharmacokinetic data will be pooled with historical adult PK data from other studies to assess whether the existing Over-the-Counter (OTC)doses provide comparable systemic drug exposure as that associated with efficacy in adults.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Doxylamine Succinate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00293644 ↗ Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy Completed Duchesnay Inc. Phase 3 2006-02-01 The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG.
NCT00293644 ↗ Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy Completed The Hospital for Sick Children Phase 3 2006-02-01 The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG.
NCT00614445 ↗ The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy Completed Premier Research Group plc Phase 3 2008-01-01 The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo.
NCT00614445 ↗ The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy Completed Duchesnay Inc. Phase 3 2008-01-01 The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo.
NCT00796315 ↗ Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Completed Consumer Healthcare Products Association Phase 1 2008-12-01 The primary goal of this study is to characterize the pharmacokinetics of doxylamine succinate in children ages 2 to < 18 years. Once characterized, these pediatric pharmacokinetic data will be pooled with historical adult PK data from other studies to assess whether the existing Over-the-Counter (OTC)doses provide comparable systemic drug exposure as that associated with efficacy in adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Doxylamine Succinate

Condition Name

Condition Name for Doxylamine Succinate
Intervention Trials
Nausea and Vomiting of Pregnancy 2
Allergic Rhinitis 1
Bioavailability 1
Hyperemesis Gravidarum 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Doxylamine Succinate
Intervention Trials
Vomiting 3
Nausea 2
Infection 1
Communicable Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Doxylamine Succinate

Trials by Country

Trials by Country for Doxylamine Succinate
Location Trials
United States 10
China 6
Canada 1
Mexico 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Doxylamine Succinate
Location Trials
District of Columbia 2
Ohio 1
North Carolina 1
Missouri 1
Louisiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Doxylamine Succinate

Clinical Trial Phase

Clinical Trial Phase for Doxylamine Succinate
Clinical Trial Phase Trials
Phase 3 4
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Doxylamine Succinate
Clinical Trial Phase Trials
Completed 4
Unknown status 1
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Doxylamine Succinate

Sponsor Name

Sponsor Name for Doxylamine Succinate
Sponsor Trials
Duchesnay Inc. 2
Affiliated Hospital of Jiamusi Medical University 1
Suihua Maternal and Child Health Hospital 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Doxylamine Succinate
Sponsor Trials
Other 16
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.